Skip to main content

Envisioning is an emerging technology research institute and advisory.

LinkedInInstagramGitHub

2011 — 2026

research
  • Observatory
  • Newsletter
  • Methodology
  • Origins
  • Vocab
services
  • Signals Session
  • Bespoke Projects
  • Build Sessions
  • Use Cases
  • Readinessfree
  • Signals
  • Free scan↗free
impact
  • ANBIMAFuture of Brazilian Capital Markets
  • IEEECharting the Energy Transition
  • Horizon 2045Future of Human and Planetary Security
  • WKOTechnology Scanning for Austria
solutions
  • Innovation
  • Strategy
  • Consultants
  • Foresight
  • Associations
  • Governments
resources
  • Partners
  • Coding for Non-Coders
  • How We Work
  • Data Visualization
  • Multi-Model Method
  • FAQ
  • Security & Privacy
about
  • Manifesto
  • Community
  • Events
  • Support
  • Contact
ResearchServicesSignalsAbout
ResearchServicesSignalsAbout
  1. Home
  2. Research
  3. Helix
  4. In-Silico Longevity Drug Repurposing Engines

In-Silico Longevity Drug Repurposing Engines

AI platforms identifying geroprotective properties in existing non-longevity drugs.
Back to HelixView interactive version

In-silico longevity drug repurposing engines are computational platforms that use AI to analyze massive pharmacological databases and real-world patient data to identify off-label geroprotective (anti-aging) effects in existing approved drugs that weren't originally developed for longevity applications, such as rapamycin or metformin alternatives. By simulating molecular docking (how drugs bind to proteins) and pathway interactions (how drugs affect biological pathways), these engines can predict which existing drugs might have anti-aging effects, significantly shortening the timeline for validating safe longevity interventions compared to developing entirely new drugs. Companies and research institutions are developing these platforms.

This innovation addresses the challenge of developing longevity therapeutics, where creating new drugs is slow and expensive, but many existing drugs might have anti-aging effects that haven't been discovered. By computationally screening existing drugs, these systems can identify promising candidates much faster than experimental screening. The approach is particularly valuable for longevity research where repurposing existing, safe drugs could accelerate progress.

The technology is particularly valuable for longevity research, where repurposing existing drugs could provide faster paths to anti-aging interventions. As the technology improves, it could become a standard approach for drug discovery in various fields. However, ensuring prediction accuracy, validating computational findings experimentally, and navigating regulatory pathways for repurposed drugs remain challenges. The technology represents an important tool for accelerating drug discovery, but requires continued development to achieve the accuracy needed for reliable predictions. Success could accelerate the development of longevity therapeutics by identifying promising existing drugs, but computational predictions must be validated experimentally and the regulatory pathway for repurposed drugs must be navigated.

TRL
8/9Deployed
Impact
4/5
Investment
3/5
Category
Software

Related Organizations

BioAge Labs logo
BioAge Labs

United States · Company

95%

Clinical-stage biotechnology company mapping molecular pathways of aging to develop therapies for immune aging.

Developer
Insilico Medicine logo
Insilico Medicine

HK · Company

95%

A clinical-stage biotechnology company using generative AI for end-to-end drug discovery and research.

Developer
Buck Institute for Research on Aging logo
Buck Institute for Research on Aging

United States · Research Lab

90%

The world's first biomedical research institution exclusively dedicated to research on aging and age-related disease.

Researcher
National Institute on Aging (NIA) logo

National Institute on Aging (NIA)

United States · Government Agency

90%

A division of the U.S. NIH dedicated to aging research.

Researcher
Ora Biomedical logo
Ora Biomedical

United States · Startup

90%

A longevity biotech company using high-throughput robotics ('WormBot') and AI.

Developer
Scheibye-Knudsen Lab

Denmark · Research Lab

90%

Lab at the University of Copenhagen focused on aging and DNA damage.

Researcher
Biovista

United States · Company

85%

A pioneer in drug repurposing using AI and project-based discovery.

Developer
Healx

United Kingdom · Company

85%

AI-powered tech company dedicated to drug repurposing for rare diseases.

Developer
Juvenescence

United Kingdom · Company

85%

A life sciences company developing therapies to modify aging.

Investor
Deep Longevity logo
Deep Longevity

HK · Company

80%

Develops deep learning biomarkers of aging (aging clocks).

Developer

Supporting Evidence

Evidence data is not available for this technology yet.

Research this in Signals

Scan In-Silico Longevity Drug Repurposing Engines for yourself.

Signals turns a topic into a sourced research record you can inspect and rerun. Your first scan is free, and this one starts with In-Silico Longevity Drug Repurposing Engines already loaded, so edit it or scan as is.